University of Nebraska Medical Center

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

Retrieved on: 
Thursday, August 18, 2022
Survival, CEO, GLOBE, Clinical trial, Cancer, Research, Marketing, Patient, Institutional review board, Food, Immune system, Erasmus, Disease, Access, Safety, Erasmus MC, Private Securities Litigation Reform Act, Nebraska Medicine, American, IRB, Regulatory affairs, Contract research organization, Monitoring, Data management, University of Nebraska Medical Center, Chronic fatigue syndrome, Investigational New Drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CRO, LLC, COVID-19, AIM, FDA, NYSE, Inspectorate, ME/CFS, Lists of diseases, Biomedical Research, LAPC, Company, Pancreatic cancer, Therapy, Myalgia, Degenerative disease, PSLRA, FOLFIRINOX, University, Human, NSF International, Pharmaceutical industry, Vaccine, Rintatolimod, Pharmacovigilance

OCALA, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — today announced the commencement of its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“LAPC”) (AMP-270) following receipt of Institutional Review Board (“IRB”) approval for the trial protocol.

Key Points: 
  • AIM Chief Executive Officer Thomas K. Equels commented, We are pleased to reach this important step in the development of Ampligen.
  • Receiving IRB approval for our Phase 2 study of Ampligen for the treatment of LAPC is the pivotal precursor to the recruitment, enrollment and treatment of patients with locally advanced pancreatic cancer.
  • The Companys Phase 2 study Investigational New Drug (IND) application was previously cleared by the U.S. Food and Drug Administration (FDA).
  • The AMP-270 clinical trial is a randomized, open-label, controlled, parallel-arm study with the primary objective of comparing the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma.

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors

Retrieved on: 
Tuesday, August 9, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Agilent Technologies, Lung cancer, Ageing, TRI, Sequoia Capital, Associate professor, Trial of the century, Internal medicine, Immunology, OS, NCCN, Female, Division, CBM, Nebraska Medicine, Group, Artificial intelligence, Research, Department, NSCLC, UnitedHealth Group, Patient, Male, Large-cell lung carcinoma, Nominal interest rate, Veterans' affairs, Lung, International Association, Personalized medicine, Â, University of Minnesota, Physician, Software, Transplant, University, University of Nebraska Medical Center, Conference, Sex, Pharmaceutical industry, Medical device, Hematology

In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.

Key Points: 
  • In the study, Singula Therapy Response Index (TRI) provided patient-specific scores that demonstrated predictive value of OS beyond NCCN-guideline genomic biomarkers, physician-prescribed treatments and standard clinical factors such as the patients age and sex.
  • The myCare-203A study found that the personalized approach of Cellworks Singula TRI produces a more precise therapeutic decision guide for patients with NSCLC.
  • The myCare-203A study shows us that the Cellworks Biosimulation Platform and Singula TRI can streamline the treatment decision-making process and improve NSCLC patient outcomes through personalized therapy response predictions.
  • These results show that physicians can use Cellworks Singula TRI scores to more precisely guide therapeutic decisions for individual patients with NSCLC.

Virtual Incision’s Miniaturized Robotic-Assisted Surgery Device Will Launch into Space in 2024

Retrieved on: 
Tuesday, August 2, 2022
Public Policy, Government, White House, Federal Government, Surgery, Health, FDA, Medical Devices, Robotics, Technology, Sale, Surgeon, University of Nebraska Medical Center, RAS, NASA, University, University of Nebraska–Lincoln, Food and Drug Administration, Industry, Food, Jet Propulsion Laboratory, International Space Station, CEO, Forward-looking statement, ISS, Research, University of Nebraska Omaha, Private Securities Litigation Reform Act, MIRA, National Aeronautics and Space Act, Establishment, Kennedy Space Center, Clinical trial, Goddard Space Flight Center, Technology, FDA, Patient, LinkedIn, International Space Station programme, IDE, Engineering, Communication, Platform, 3D printing, Pharmaceutical industry, Facebook

Virtual Incision Corporation , a medical device company pioneering the worlds first miniaturized robotic-assisted surgery (RAS) platform, today announced that its MIRA Platform will test its skills in space on a 2024 technology demonstration mission aboard the International Space Station (ISS).

Key Points: 
  • Virtual Incision Corporation , a medical device company pioneering the worlds first miniaturized robotic-assisted surgery (RAS) platform, today announced that its MIRA Platform will test its skills in space on a 2024 technology demonstration mission aboard the International Space Station (ISS).
  • Working with NASA aboard the space station will test how MIRA can make surgery accessible in even the most faraway places.
  • Prior to Virtual Incision, Farritor studied at the Kennedy Space Center, Goddard Space Flight Center, and the Jet Propulsion Laboratory.
  • Virtual Incisions MIRA is the worlds first miniaturized robotic-assisted surgery (RAS) platform.

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development

Retrieved on: 
Monday, July 25, 2022
Nuclear physics, SL, Psychiatry, Monkeypox, Infection, CNS, Company, Security (finance), Smallpox, Running, Translational research, Prader–Willi syndrome, Research, U.S. Securities and Exchange Commission, Cancer, University, Cocaine, Pain, Neurology, IND, Long COVID, GLOBE, Fibromyalgia, Industry, SEC, Government, Disease, RDC, Hydrogen chloride, Failure, COVID-19, Pharmacy, Achievement, Central nervous system, Nuclear pharmacy, Autoimmunity, FDA, Nebraska Medicine, CD154, University of Nebraska Medical Center, Nasdaq, Therapy, Annual report, Risk, Vaccine, Bavari, Private Securities Litigation Reform Act, USAMRIID, Leadership, United States Army Research Institute of Environmental Medicine, Investigational New Drug, Education Development Center, Degenerative disease, Pharmaceutical industry, Tonix Pharmaceuticals, Immunology

CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.

Key Points: 
  • CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research and Development.
  • and, as part of his role, will oversee scientific development at Tonixs Infectious Disease R&D Center located there.
  • We are delighted that Dr. Bavari has joined our team to lead our infectious disease research and development efforts, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.
  • I am excited to join Tonix and to lead the Company's efforts in infectious disease research and development programs, including vaccines in development for monkeypox, smallpox and COVID-19, said Dr. Bavari.

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Retrieved on: 
Wednesday, July 20, 2022
Erasmus MC, CFS, Congress, University, GLOBE, Lists of diseases, Inspectorate, Lead, Doctor of Philosophy, LAPC, NYSE, Research, Pancreatic cancer, AIM, CRO, Private Securities Litigation Reform Act, Intention, Cancer, Chronic fatigue syndrome, Immune system, COVID-19, Safety, Clinical trial, EAP, Disease, Nebraska Medicine, Company, MD, UNMC, University of Nebraska Medical Center, Patient, American, PSLRA, Medi-Cal Access Program, Overalls, Professor, Therapy, Survival, Hope, Progression-free survival, Program, FOLFIRINOX, Observation, Degenerative disease, Pharmaceutical industry, Rintatolimod

OCALA, Fla., July 20, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today reported follow-on data from its previously published single-center named patient program. For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (See: Cancers 2022).

Key Points: 
  • For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (See: Cancers 2022 ).
  • Multi-year survival rates for LAPC and metastatic pancreatic cancer patients are historically low, with 5-year survival typically less than 3%.
  • These additional data, indicating major improvements to survival at 24 months and beyond, point to the potential value of Ampligen as a therapy for pancreatic cancer patients.
  • The data bolster our confidence in the potential of Ampligen for the treatment of late-stage pancreatic cancer and represents a big step forward in Ampligens therapeutic development program.

ATCC Expands Leadership Team to Provide Vision and Growth Strategy

Retrieved on: 
Tuesday, July 12, 2022
Science, Public Policy, Government, Other Science, Biotechnology, Research, White House, Federal Government, Health, Infectious Diseases, Linda, Public health, COVID-19, United States Patent and Trademark Office, Friends, Monkeypox, PATH, Master of Business Administration, Leadership, Forest Law Enforcement and Governance Program, Board of directors, University of Nebraska Medical Center, History, JDRF, Drug discovery, CEO, Government, IP, Director, Bradford, Chemistry, Intellectual property, Carey Business School, Invention, Johns Hopkins University, Technology transfer, Doctor of Philosophy, Collection, Intellectual, Business administration, Kantar Group, Negotiation, Research, Growth, Board, University, Patent, Industry, Partnership, AFS, Nebraska Medicine, Management, Pharmaceutical industry, Science, Biotechnology, Biology, ATCC

Both positions will continue to bring leadership and vision to ATCC's growth strategy.

Key Points: 
  • Both positions will continue to bring leadership and vision to ATCC's growth strategy.
  • Since joining the company in 2004, Bradford has been essential to the expansion of AFS's client base and strengthened its infrastructure to support its growth strategy.
  • "My congratulations to Rebecca on her promotion," said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • "Linda is responsible for the revitalization and growth of the Licensing and IP leadership team, responsible for overall strategy, management, and infrastructure," remarked Dr. Cypess.

National Cancer Center Announces Recipients of 2022-23 Research Fellowship Awards

Retrieved on: 
Thursday, June 30, 2022
Science, Other Philanthropy, Research, Oncology, Health, Philanthropy, Fund Raising, Foundation, Melanoma, Diagnosis, New York University Grossman School of Medicine, University of Nebraska Medical Center, Rockefeller University, Research, Harvard Medical School, Icahn School of Medicine at Mount Sinai, National Cancer Center, Death, Man, Nebraska Medicine, NCC, Cancer, Brain, University of Pittsburgh, University of California, PAP, Prostate cancer, Coronavirus Scientific Advisory Board (Turkey), UPMC Hillman Cancer Center, Woman, Therapy, Dana–Farber Cancer Institute, Education, University, Cleveland Clinic, Duke University Hospital, City, DNA, Cervical cancer, McMaster University Medical School, Johns Hopkins School of Medicine, Time, DNA repair, Massachusetts General Hospital, Interferon, Baylor College of Medicine, Pharmaceutical industry, Management, Medicine, Doctor of Philosophy

The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2022-23 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • This growing public support also enabled National Cancer Center to increase the size of its awards by a significant margin.
  • National Cancer Centers mission is to fill an often-overlooked role in the quest to cure cancer by identifying and funding promising projects by the best up-and-coming research fellows, said Regina English, Executive Director of the National Cancer Center.
  • National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as a non-profit organization committed to research and education about cancer.

Bone Health Technologies and San Francisco VA Health Care System with University of California, San Francisco to Begin Osteoporosis Prevention Study for Postmenopausal Women with Osteopenia

Retrieved on: 
Monday, June 20, 2022
Department, FDA, University of California, San Francisco, Biostatistics, Science, Bone resorption, Epidemiology, CEO, Research, Company, Bone, University of Nebraska Medical Center, Man, Trial of the century, UCSF, DXA, Metabolism, Risk, Urine, GLOBE, University, Department of Medicine – University of Pamplona, CT, Bone density, Vibration, Hip, Associate, Osteopenia, Partnership, Patient, Board, NASA, Osteoporosis, BHT, SAN, Woman, Goal, NIH, Pharmaceutical industry, Medical device, Medical imaging, Dietary supplement, Medicine, Endocrinology

The UCSF/SFVAHCS teams will rigorously test the nonpharmacologic intervention, which could be incorporated into the preventive regimens recommended to postmenopausal women.

Key Points: 
  • The UCSF/SFVAHCS teams will rigorously test the nonpharmacologic intervention, which could be incorporated into the preventive regimens recommended to postmenopausal women.
  • A key vision of this project is that this device be tested in women of diverse racial and ethnic backgrounds.
  • There will be urine and serum measurements of bone cell activity, reflecting both bone formation and bone resorption, before and during use of the OsteoBoost technology.
  • Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis).

Gallup Announces New CEO

Retrieved on: 
Tuesday, June 14, 2022
Data Analytics, Consulting, Marketing, Communications, Professional Services, Life, International law, Congo, Foreign Affairs Policy Board, Policy, CEO, Meridian International Center, The Fidelity Ultimate Chess Challenge, University, Organization, Workforce, Multimedia, Young Professionals in Foreign Policy, Baylor University, Student, Carlyle, University of Nebraska Medical Center, Sadness, Foreign Policy, Board, History, Republic, Institute, Gallup (company), Management, Midland University, Gallup, Religion

Gallup, the global analytics and advisory firm, announces today that it has named Jon Clifton its new Chief Executive Officer.

Key Points: 
  • Gallup, the global analytics and advisory firm, announces today that it has named Jon Clifton its new Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20220613005839/en/
    Jon Clifton, Gallup Chief Executive Officer (Photo: Gallup)
    Clifton, who has been with Gallup since 2008, had most recently served as the firms Global Managing Partner for five years, advising global leaders on how their organizations and countries can thrive using analytics-based insights.
  • Cliftons upcoming book, Blind Spot: The Global Rise of Unhappiness and How Leaders Missed It , will be released by Gallup Press in September.
  • Jim Clifton, who had served as the firms previous CEO since 1988, will remain as Chairman of the Board.

Pharos Capital Group Adds Two Vice Presidents

Retrieved on: 
Wednesday, June 1, 2022
Leadership, Economics, Wharton School of the University of Pennsylvania, Associate, CEO, Family, Investment, University, Norwest Venture Partners, University of Nebraska Medical Center, BSBA, Real estate, University of Nebraska Omaha, University of Waterloo School of Accounting and Finance, Morehouse College, Lighthouse of Alexandria, Barclays Investment Bank, Chief executive officer, Management, Philip, Accounting

DALLAS and NASHVILLE, Tenn., June 1, 2022 /PRNewswire/ -- Pharos Capital Group, a middle-market private equity firm based in Dallas and Nashville, announced today that it recently added two vice presidents to its team. Jim Kerrigan, in the firm's Dallas office, was promoted from Associate. The firm also hired Philip Butler as a Vice President in its Dallas office. The moves are part of Pharos's continuing efforts to both recognize home-grown talent and recruit talented outside professionals to support the firm's growth.

Key Points: 
  • DALLAS and NASHVILLE, Tenn., June 1, 2022 /PRNewswire/ -- Pharos Capital Group, a middle-market private equity firm based in Dallas and Nashville, announced today that it recently added two vice presidents to its team.
  • The firm also hired Philip Butler as a Vice President in its Dallas office.
  • Kneeland Youngblood, Pharos Founding Partner and Chairman & CEO, said, "Pharos is proud to recognize Jim and Philip in their new roles.
  • For business development opportunities with Pharos Capital Group, please contact Adam Persiani at 214-740-7003 or [email protected] .